drugset
drugset / Trial / NCT04463615

Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders

NCT04463615 ↗

Phase 2 Completed 1 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2021-05-05
Primary completion
2021-07-28
Completion
2021-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule — —

Indications

lymphoproliferative syndrome